BMJ  2005;330:917 (23 April), doi:10.1136/bmj.330.7497.917

Editorial

New arrangements for the Medicines and Healthcare products Regulatory Agency

Offer lay involvement, fewer competing interests, and better decision making

The first 150 words of the full text of this article appear below.

Major changes are occurring at the Medicines and Healthcare products Regulatory Agency (MHRA) and these hold promise for real advance. The events of the last weeks and months give important insights into the changes now underway.

On 5 April the House of Commons health select committee in its report on the influence of the pharmaceutical industry found that the agency was complacent, lacking the competence to act as a licensing authority. It recommended that the agency be subject to an independent review. On 7 April, government laid before parliament the Medicines (Advisory Bodies) Regulations,1 presaging the abolition of the agency's two key advisory bodies—the Medicines Commission and the Committee on the Safety of Medicines—both essentially unchanged since the early 1970s. On 13 April the national press carried advertisements inviting senior professionals and representatives of patients and consumers to fill posts in the new system.

To these recent events one . . . [Full text of this article]

Joe Collier, professor of medicines policy

St George's, University of London, London SW17 0RE (jcollier@sghms.ac.uk)


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Regulating herbal medicines in the UK
Robin E Ferner and Keith Beard
BMJ 2005 331: 62-63. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Ferner, R. E, Beard, K. (2005). Regulating herbal medicines in the UK. BMJ 331: 62-63 [Full text]  
Access jobs at BMJ Careers
Whats new online at Student BMJ